Abstract OT1-04-01: Adjuvant ovarian suppression plus aromatase inhibitor or tamoxifen for hormone receptor-positive breast cancer in women younger than 35 (ASPAIT): A multicenter randomized clinical trial
Shan, Zhen, Shao, Nan, yuan, Zhongyu, Chen, Qianjun, Zhang, Anqin, Wang, Kun, Zhang, Ailing, Cai, Li, Song, Yuhua, Yao, Herui, Ma, Hongmin, Huang, Heng, Li, Jianwen, Zhang, Yuanqi, Zhang, Lehong, Zhong, Jincai, Liu, Hui, Wu, Zhiyong, Zhao, Li, Ling, Feihai, Yang, Weixiong, Zhuo, Rui, Song, Xiangyang, Lin, Ying
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Get full text
Journal Article